Indaptus Therapeutics, Inc.INDPNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank8
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P8
Near historical low
vs 5Y Ago
-5.1x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -29.97% |
| Q2 2025 | -22.90% |
| Q1 2025 | 13.34% |
| Q4 2024 | 69.16% |
| Q3 2024 | -14.47% |
| Q2 2024 | 7.72% |
| Q1 2024 | -21.80% |
| Q4 2023 | -8.63% |
| Q3 2023 | 50.40% |
| Q2 2023 | -21.25% |
| Q1 2023 | -1.67% |
| Q4 2022 | 18.78% |
| Q3 2022 | 6.86% |
| Q2 2022 | 16.12% |
| Q1 2022 | 37.31% |
| Q4 2021 | 35.40% |
| Q3 2021 | 78.38% |
| Q2 2021 | -20.13% |
| Q1 2021 | 39.07% |
| Q4 2020 | -73.91% |
| Q3 2020 | 5.87% |
| Q2 2020 | 240.51% |
| Q1 2020 | -79.30% |
| Q4 2019 | -78.59% |
| Q3 2019 | 7.48% |
| Q2 2019 | -7.98% |
| Q1 2019 | -17.17% |
| Q4 2018 | 32.07% |
| Q3 2018 | -7.04% |
| Q2 2018 | -5.41% |
| Q1 2018 | 0.12% |
| Q4 2017 | 50.63% |
| Q3 2017 | 4.75% |
| Q2 2017 | 43.50% |
| Q1 2017 | 0.00% |
| Q4 2015 | 37.38% |
| Q3 2015 | 16.73% |
| Q2 2015 | 274.96% |
| Q1 2015 | 0.00% |